Aurinia announces publication of AURORA 1 phase III study results with Lupkynis for the treatment of lupus nephritis in The Lancet.

Aurinia Pharmaceuticals Inc. announced that The Lancet, an international, peer-reviewed medical journal, published the results of the Company’s Phase III AURORA 1 study evaluating Lupkynis (voclosporin) in adults with lupus nephritis (LN). The AURORA 1 study results demonstrate that Lupkynis in combination with mycophenolate mofetil (MMF) and low-dose corticosteroids led to statistically superior complete renal response rates at 52 weeks compared to treatment with MMF and low-dose corticosteroids alone, with a comparable safety profile. In fact, separation in efficacy between treatment groups was observed as early as 4 weeks. MMF and corticosteroids are typical SoC immunosuppressive agents used for the treatment of LN. On January 22, 2021, the FDA approved Lupkynis in combination with a background immunosuppressive therapy regimen to treat adult patients with active LN. < See; "Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase III trial."Prof Brad H Rovin, MD, Y K Onno Teng, MD, ,et al. Published:May 07, 2021DOI:https://doi.org/10.1016/S0140-6736(21)00578-X.